Role of the protein tyrosine phosphatase SHP-1 in Interleukin-6 regulation of prostate cancer cells

Prostate

Volumn 70, Issue 14, 2010, Pages 1491-1500

  Tassidis, Helena ^a   Culig, Zoran ^b   Wingren, Anette Gjörloff ^a,c   Härkönen, Pirkko ^a  

^a LUND UNIVERSITY   (Sweden)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MALMÖ UNIVERSITY   (Sweden)

Author keywords

Apoptosis; IL 6; Proliferation; Prostate cancer cells; PTEN

Indexed keywords

CASPASE 3; COMPLEMENTARY DNA; CYTOKINE; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 1; RECOMBINANT INTERLEUKIN 6; SMALL INTERFERING RNA; STAT3 PROTEIN; TYROSINE KINASE RECEPTOR; CASPASE 7; PRIMER DNA; PTEN PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER PATIENT; CELL CULTURE; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTINUOUS CULTURE; CONTROLLED STUDY; DNA MICROARRAY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CELL DIVISION; DISEASE COURSE; DOWN REGULATION; ENZYMOLOGY; GENETICS; KINETICS; LYMPH NODE METASTASIS; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CASPASE 3; CASPASE 7; CELL DIVISION; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA PRIMERS; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; KINETICS; LYMPHATIC METASTASIS; MALE; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 77957007177     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21184     Document Type: Article

References (30)

1. Trikha M, Corringham R, Klein B, Rossi JF,. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 2003; 9 (13): 4653 -4665.
2. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z,. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998; 58 (20): 4640 -4645.
3. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Klocker H, Bartsch G, Culig Z,. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000; 191 (3): 239 -244.
4. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW,. Interleukin-6: A candidate mediator of human prostate cancer morbidity. Urology 1995; 45 (3): 542 -549.
5. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M,. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6 (7): 2702 -2706.
6. Culig Z, Steiner H, Bartsch G, Hobisch A,. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005; 95 (3): 497 -505.
7. Corcoran NM, Costello AJ,. Interleukin-6: Minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 2003; 91 (6): 545 -553.
8. Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, Wang PH, Chen YT, Chang C,. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun 2003; 305 (3): 462 -469.
9. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW,. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999; 38 (3): 199 -207.
10. Neel BG, Gu H, Pao L,. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003; 28 (6): 284 -293.
11. Yu Z, Su L, Hoglinger O, Jaramillo ML, Banville D, Shen SH,. SHP-1 associates with both platelet-derived growth factor receptor and the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem 1998; 273 (6): 3687 -3694.
12. Tomic S, Greiser U, Lammers R, Kharitonenkov A, Imyanitov E, Ullrich A, Bohmer FD,. Association of SH2 domain protein tyrosine phosphatases with the epidermal growth factor receptor in human tumor cells. Phosphatidic acid activates receptor dephosphorylation by PTP1C. J Biol Chem 1995; 270 (36): 21277 -21284.
13. Keilhack H, Tenev T, Nyakatura E, Godovac-Zimmermann J, Nielsen L, Seedorf K, Bohmer FD,. Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling. J Biol Chem 1998; 273 (38): 24839 -24846.
14. Massa PT, Saha S, Wu C, Jarosinski KW,. Expression and function of the protein tyrosine phosphatase SHP-1 in oligodendrocytes. Glia 2000; 29 (4): 376 -385.
15. Wu C, Guan Q, Wang Y, Zhao ZJ, Zhou GW,. SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J Cell Biochem 2003; 90 (5): 1026 -1037.
16. Zapata PD, Ropero RM, Valencia AM, Buscail L, Lopez JI, Martin-Orozco RM, Prieto JC, Angulo J, Susini C, Lopez-Ruiz P, Colas B,. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. J Clin Endocrinol Metab 2002; 87 (2): 915 -926.
17. Tassidis H, Brokken LJ, Jirstrom K, Ehrnstrom R, Ponten F, Ulmert D, Bjartell A, Harkonen P, Gjorloff Wingren A,. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer. Int J Cancer 2010; 126 (10): 2296 -2307.
18. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z,. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 2001; 7 (9): 2941 -2948.
19. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, Culig Z,. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 2003; 162 (2): 655 -663.
20. Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H,. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 2004; 58 (3): 259 -268.
21. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J,. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998; 58 (13): 2720 -2723.
22. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP,. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999; 41 (2): 127 -133.
23. Sarker D, Reid AH, Yap TA, de Bono JS,. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15 (15): 4799 -4805.
24. Mori R, Xiong S, Wang Q, Tarabolous C, Shimada H, Panteris E, Danenberg KD, Danenberg PV, Pinski JK,. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate 2009; 69 (1): 12 -23.
25. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW,. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/-mice. Cancer Res 2000; 60 (13): 3605 -3611.
26. Witkiewicz A, Raghunath P, Wasik A, Junkins-Hopkins JM, Jones D, Zhang Q, Odum N, Wasik MA,. Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma. Hum Pathol 2007; 38 (3): 462 -467.
27. Oka T, Yoshino T, Hayashi K, Ohara N, Nakanishi T, Yamaai Y, Hiraki A, Sogawa CA, Kondo E, Teramoto N, Takahashi K, Tsuchiyama J, Akagi T,. Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: Combination analysis with cDNA expression array and tissue microarray. Am J Pathol 2001; 159 (4): 1495 -1505.
28. Wu C, Sun M, Liu L, Zhou GW,. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003; 306: 1 -12.
29. Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T,. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol 1996; 16 (12): 6985 -6992.
30. Ram PA, Waxman DJ,. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J Biol Chem 1997; 272 (28): 17694 -17702.